

Byooviz[™] (ranibizumab-nuna) – New biosimilar launch

- On June 2, 2022, [Biogen](#) and [Samsung Bioepis announced](#) the launch of [Byooviz \(ranibizumab-nuna\)](#), a biosimilar to Genentech's [Lucentis[®] \(ranibizumab\)](#).
 - Byooviz will be commercially available on July 1, 2022.
- The [FDA approved](#) Byooviz in September 2021 for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.
 - Additional information about Byooviz may be found in a previous [Clinical news summary](#).
- Lucentis is also approved for the treatment of diabetic macular edema and diabetic retinopathy.
- The list price for Byooviz will be \$1,130 per single use vial to administer 0.5 mg via intravitreal injection, which is 40% lower than the current list price of Lucentis.